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Background: Abnormal cerebral perfusion during the first 
days of life in preterm infants is associated with higher grades of 
intraventricular hemorrhages and lower developmental score. 
In SafeBoosC II, we obtained a significant reduction of cerebral 
hypoxia by monitoring cerebral oxygenation in combination 
with a treatment guideline. Here, we describe (i) difference in 
brain injury between groups, (ii) feasibility of serial cranial ultra-
sound (cUS) and magnetic resonance imaging (MRI), (iii) local 
and central cUS assessment.
Methods: Hundred and sixty-six extremely preterm infants 
were included. cUS was scheduled for day 1, 4, 7, 14, and 35 
and at term-equivalent age (TEA). cUS was assessed locally 
(unblinded) and centrally (blinded). MRI at TEA was assessed 
centrally (blinded). Brain injury classification: no, mild/moder-
ate, or severe.
results: Severe brain injury did not differ significantly 
between groups: cUS (experimental 10/80, control 18/77, 
P = 0.32) and MRI (5/46 vs. 3/38, P = 0.72). Kappa values for 
local and central readers were moderate-to-good for severe 
and poor-to-moderate for mild/moderate injuries. At TEA, cUS 
and MRI were assessed in 72 and 64%, respectively.
conclusion: There was no difference in severe brain injury 
between groups. Acquiring cUS and MRI according the stan-
dard operating procedures must be improved for future trials. 
Whether monitoring cerebral oxygenation during the first 72 h 
of life prevents brain injury should be evaluated in larger mul-
ticenter trials.
the circulatory adaption to birth is problematic for the vulnerable preterm infant. The immature respiratory and 
circulatory systems may cause episodes of cerebral hypoxia, 
which may lead to brain injury. Near-infrared spectroscopy 
(NIRS) has been used to monitor tissue oxygenation, and 
abnormal cerebral perfusion has been associated with higher 
grades of intraventricular hemorrhages and lower neurodevel-
opmental scores at 2 y of age (1,2). The multicenter feasibil-
ity trial SafeBoosC II (3) demonstrated that cerebral NIRS in 
combination with a dedicated treatment guideline (4) was able 
to reduce the median burden of cerebral hypo- and hyperoxia 
by 58% (95% confidence interval: 35–73%; P < 0.001) com-
pared with a control group with blinded collection of NIRS 
data and treatment as usual (5). Hypoxia was reduced, while 
hyperoxia was unaffected. Whether the experimental interven-
tion prevents brain injury remains to be determined.
Cranial ultrasound (cUS) is the most widely used neuroim-
aging tool for assessing brain injury in preterm infants, and 
cUS findings are often reported as an outcome measure in 
randomized clinical trials. The advantages of cUS are that it 
causes minimal disturbance to the preterm infant, has no side 
effects, can be conducted at the bedside, is easy to repeat as 
often as indicated, and is relatively inexpensive. Furthermore, 
severe brain injury as assessed by cUS correlates well with 
later neurodevelopmental outcome; hence, cUS, especially 
sequentially, can be used to predict later neurodevelopmental 
outcome (6–9). Magnetic resonance imaging (MRI) at term-
equivalent age (TEA) though is superior to cUS in predict-
ing neurodevelopmental outcome and cerebral palsy at 2 y of 
age (10,11). More recently, it has been suggested that MRI can 
be used for the evaluation of neuroprotective treatments by 
quantitative applications (12–14) as subtle differences in brain 
development can be detected (15). Thus, MRI may reduce the 
number of infants needed for future randomized neuropro-
tective trials. Additionally, MRI has been suggested for rou-
tine use in clinical settings for high-risk extremely preterm 
infants (13).
In SafeBoosC II, brain injury assessed by serial cUS was a 
secondary outcome and MRI at TEA was an explorative out-
come. The aims of the present study were (i) to assess the dif-
ference in brain injury between the two treatment groups of 
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the SafeBoosC II trial, (ii) to describe the feasibility of neu-
roimaging (cUS and MRI) according to a standard operat-
ing procedure, and (iii) to explore the differences between 
interobserver agreement of central and local readings of serial 
cUS in this randomized multicenter feasibility trial.
RESULTS
Birth weight and gestational age did not differ between the 
experimental and the control groups (Table 1).
Differences in Brain Injury Between Groups
Cranial ultrasound
Local reading. The distribution of brain injury severity did not 
differ at any time-point between the experimental and the con-
trol groups; neither did the overall cUS-score.
Central reading. The raw and unadjusted P values for the 
between-group analysis showed a significant difference in the 
distributions of brain injury on day 1 (P = 0.043) and at TEA 
(P = 0.01), whereas the secondary outcome of the SafeBoosC II 
trial, the overall cUS score, did not differ significantly between 
the groups (P = 0.053). The number of severe injuries was 
lower in the experimental than in the control group, whereas 
the number of mild injuries was higher in the experimental 
than in the control group (Table 2). The odds ratio of severe 
brain injury vs. no severe brain injury was insignificant at all 
time points and for the overall cUS score. There were fewer 
severe intracranial hemorrhages (IVH grade III and periven-
tricular hemorrhagic infractions) in the experimental group 
(8/80 (10%)) than in the control group (14/77 (18.2%)), but 
this was not significant (odds ratio 0.50 (95% confidence inter-
val: 0.20–1.27)).
In 25 of the 28 preterm infants with severe brain injury, this 
was detected within the first 7 d of life. In the remaining three 
infants, severe brain injury on cUS was diagnosed by day 35 
(posthemorrhagic ventricular dilatation, day 14; local cystic 
lesion, day 35; and cerebral atrophy, day 35).
Magnetic resonance imaging
Twenty-four MRIs conducted within the predefined corrected 
gestational age of 40–44 wk in each group were assessed 
(n = 48; Table 3). MRIs done outside the predefined corrected 
table 1. Patient characteristics
Experimental 
group Control group
Infants included in SafeBoosC II n = 86 n = 80
   Gestational age (wk), median 
(range)
26.9 (23.9–27.9) 26.9 (23.4–27.9)
  Birth weight (g), median (range) 806 (410–1,286) 880 (480–1,330)
Infants with central overall cUS score n = 80 n = 77
   Gestational age (wk), median 
(range)
26.6 (23.9–27.9) 27.0 (23.4–27.9)
  Birth weight (g), median (range) 806 (410–1,286) 880 (490 - 1330)
Infants with MRI at any time n = 49 n = 38
   Gestational age (wk), median 
(range)
27.0 (23.9–27.9) 26.7 (24.0–27.9)
  Birth weight (g), median (range) 806 (520–1,180) 900 (515–1,330)
Infants with MRI at corrected age 
40–44 wk
n = 28 n = 29
   Gestational age (wk), median 
(range)
26.7 (23.9–27.9) 27.0 (24.9–27.9)
  Birth weight (g), median (range) 800 (520–1,180) 934 (700–1,330)
cUS, cranial ultrasound; MRI, magnetic resonance imaging.
table 2. Brain injury severity for each of the sequential and the overall cUS score as assessed by central reading
Day 1 Day 4 Day 7 Day 14 Day 35 TEA Overall cUS score
Experimental group (n = 80)
  No scan/central score (n) 6 7 4 9 4 24 —
  Death (n) 0 2 3 6 10 10 —
  No injury (n) 54 42 44 30 32 10 21
  Mild/moderate injury (n) 19 22 22 27 29 31 49
  Severe injury (n) 1 7 7 8 6 5 10
Control group (n = 77)
  No scan/central score (n) 6 3 3 4 10 12 —
  Death (n) 0 3 9 13 15 19 —
  No injury (n) 55 41 36 26 23 23 26
  Mild/moderate injury (n) 10 18 18 24 19 17 33
  Severe injury (n) 6 12 11 10 10 6 18
χ2 test, P valuea 0.043 0.42 0.44 0.78 0.26 0.01 0.053
Severe vs. no severe brain injuryb
Odds ratio  
(95% confidence interval)
0.15 (0.02–1.27) 0.54 (0.20–1.46) 0.52 (0.19–1.44) 0.70 (0.26–1.92) 0.41 (0.14–1.22) 0.81 (0.23–2.88) 0.47 (0.20–1.09)
cUS, cranial ultrasound; TEA, term-equivalent age.
aχ2 analysis of the between-group distribution of brain injuries in the three categories: no injury, mild/moderate injury, and severe injury. bOdds ratio for severe vs. no severe (no/mild/
moderate) brain injury.
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gestational age of 40–44 wk (n = 30 there of three with arti-
facts) and MRIs with movement artifacts (n = 4) or slice thick-
ness above 2 mm unless severe injury was clearly seen (n = 5) 
were excluded. MRI brain injury scores did not differ between 
the two groups. Analysis including MRI at any time point (46 
infants in the experimental group and 38 infants in the con-
trol group) was also carried out, and there was no difference 
between the groups (Table 3).
Discrepancies between cUS and MRI findings
None of the cUSs or MRIs scored as no brain injury was scored 
as severe in the other imaging modality, but in five of the MRI 
conducted within the predefined gestational age of 40 to 44 wk, 
there was disagreement of mild/moderate in one modality com-
pared to severe brain injury in the other. Two preterm infants 
with IVH grade 1 or 2 seen on cUS (mild/moderate brain injury) 
on day 1 and day 7, respectively, were classified as severe brain 
injury on MRI (Kidokoro score of 12) (16). Both had cerebellar 
hemorrhages and additionally increased subarachnoid space or 
cerebral occipital atrophy, which was not identified by cUS.
One preterm infant had IVH grade III (day 7) and subse-
quently developed posthemorrhagic ventricular dilatation on 
cUS. MRI at TEA confirmed posthemorrhagic ventricular dila-
tation; however, according to the MRI Kidokoro scoring system, 
this resulted in mild/moderate global injury score, since the 
ventricles had returned to almost normal sizes (16). Cerebellar 
hemorrhage was seen on cUS in one preterm infant resulting in a 
severe cUS injury score. As there were no additional lesions and 
the cerebellar hemorrhage was unilateral on MRI, this resulted in 
mild/moderate global MRI injury score (16). A lenticulo-striatal 
stroke was seen on cUS in one preterm infant, this was classi-
fied as severe cUS brain injury. On MRI at TEA, the atrophy of 
the stroke area could be seen; however, in the global brain injury 
score, the sum of all lesions yielded a mild/moderate injury score.
Twenty-seven MRIs performed at other time points than cor-
rected gestational age 40 to 44 wk were assessed. Four of these 
had severe brain injury on cUS, which in two of the cases also 
was identified on MRI. In the other two infants with severe brain 
injury on cUS, one infant was diagnosed on day 1 with unilat-
eral hemorrhagic infarction; however, the MRI at 49 wk showed 
mild/moderate injury. The other infant was diagnosed with a 
lenticulostriatal stroke on cUS day 4 and the MRI at 47 wk of cor-
rected gestational age showed mild/moderate injury.
Feasibility
Cranial ultrasound
Eight-hundred and thirteen of the 887 planned cUS series (cUSs 
as described in the cUS-standard operating procedure from birth 
to time of death or TEA) were available for central reading, each 
series consisting of up to 12 images. In 32 series, the quality was 
too poor for central image analysis. Seven-hundred and eighty-one 
(88%) of the planned cUS series were thus scored centrally. The 
number of uploaded and centrally scored cUS series was highest 
on day 7 (experimental group 95%, control group 96%) and lowest 
at TEA (experimental group 66%, control group 79%; Figure 1). 
In total, only 55% of the infants in the experimental and 65% in the 
control group had all cUS from day 1 till TEA or death.
Local overall cUS score was calculated in 165 out of 166 
infants; 1 infant died prior to the first cUS. One-hundred and 
fifty-seven (157/166) infants (95%) had an overall central cUS 
score. Reasons for no central overall cUS score were death 
prior to the first cUS (n = 1), too few uploaded image series 
per patient (less than 3 cUS; n = 1), poor quality of the images 
(n = 3), or a combination of both (n = 4). Three of the infants 
without an overall central cUS score died before TEA, two in 
the experimental and one in the control group.
Magnetic resonance imaging 
Eighty-seven (65%) of the 134 infants alive at TEA had an MRI. 
Median (range) corrected age at the time of the MRI was 41.4 wk 
(range: 36.8–53.9). Fifty-seven (66%) of the MRIs were conduct-
ed within the predefined corrected gestational age of 40 to 44 wk 
(median (range)) 41.4 wk (40.0–44.0) in accordance with the MRI-
standard operating procedure. The reasons for no MRI were: lack 
of parental consent (n = 29), the infant could not lie still (n = 3), or 
other reasons such as technical problems, child discharged to other 
department, or failure to turn up at the appointment (n = 15).
Central vs. local readings cUS 
Kappa values between the local and central readers were high-
est for periventricular hemorrhagic infarction (κ = 0.79 at 
day 7 and 0.75 at day 14) and posthemorrhagic ventricular 
table 3. MRI brain injury severity between experimental and control group
MRI at corrected age 40–44 wk Experimental group (n = 24) Control group (n = 24) P valuea
  Corrected age (wk), median (range) 41.4 (40.7–43.6) 41.2 (40.3–44.0)
  No injury, n (%) 3 (13) 2 (8)
  Mild/moderate injury, n (%) 18 (74) 19 (79) 0.89
  Severe injury, n (%) 3 (13) 3 (13)
MRI at any time point n = 46b n = 38 P valuea OR (95% CI)
  Corrected age (wk), median (range) 41.4 (36.7–52.7) 41.4 (39.8–53.9)
  No severe brain injury, n (%) 41 (89) 35 (89)
  Severe injury, n (%) 5 (11) 3 (8) 0.72 1.4 (0.3–6.4)
CI, confidence interval; MRI, magnetic resonance imaging.
aχ2 test for equal distribution of brain injuries between the groups. bThree infants were excluded from the analysis as the quality of the MRI was of insufficient quality.
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 dilatation (κ = 1 at day 7 and 0.72 at day 14), whereas the low-
est κ values were found for intraventricular hemorrhage grade 
I and II (κ = 0.32 at day 1 and 0.34 at day 4) and persisting in-
homogeneous flaring at day 14 (κ = 0.04). Kappa values (95% 
confidence interval) for the overall cUS score no, mild/moder-
ate or severe brain injury was 0.61 (0.49–0.72) for the central 
readers and 0.40 (0.29–0.51) for local vs. central. Interobserver 
κ value for the overall cUS score for severe vs. no severe injury 
between the two central readers was 0.86 (0.75–0.96), whereas 
the agreement between the local and central reading was 0.57 
(0.41–0.74). These κ values were similar for the images scored 
in DICOM- and in other formats.
DISCUSSION
Differences in Brain Injury Between Groups
The odds ratio of severe brain injury vs. no severe brain injury 
was insignificant at all time points and for the overall cUS 
score. In addition, conventional MRI did not suggest any dif-
ferences between the two groups. However, cUS findings were 
only a secondary outcome and MRI an explorative outcome 
in the SafeBoosC II trial; therefore, the study was not powered 
to look at differences in brain injury between the two groups. 
More infants in the control group than in the experimental 
group had severe brain injuries at day 1, although the patient 
characteristics were similar. As the infants did not have cUS 
before inclusion of the trial, it is not possible to determine if 
these numbers reflect an early effect of the intervention or if it 
was present before the inclusion. Therefore, inclusions imme-
diately after birth or neuroimaging before intervention are 
considerations for future studies.
The number of severe brain injury as assessed by blinded 
central cUS reading was lowest in the experimental group, 
mainly due to fewer cases of severe intracranial hemorrhages, 
as compared with the control group during the first week of life. 
However, there were more mild injuries on cUS in the infants 
in the experimental group compared with the control group. 
This could be a result of a shift from severe brain injury and 
death, which was highest in the control group, toward more 
mild injuries. This finding was not confirmed on MRI at TEA.
There is no gold standard for monitoring cerebral tissue oxy-
genation; therefore, the target values of cerebral oxygenation 
(55–85%) in the SafeBoosC II trial are based on the best pos-
sible evidence, which is the 95% confidence interval of cere-
bral NIRS values in 439 preterm infants born below 32 wk of 
gestation within the first 3 d of life (P. Lemmers and F. van Bel, 
unpublished data). In the SafeBoosC II trial, NIRS monitoring 
in combination with a dedicated treatment guideline for cere-
bral tissue oxygenation out of range was able to significantly 
reduce the burden of cerebral hypoxia during the first 72 h of 
life (5). It has previously been reported that low cerebral NIRS 
values in preterm infants during the first days of life are asso-
ciated with higher grades of intraventricular hemorrhage and 
lower developmental quotients in very preterm infants (1,2,17), 
but in this study, we did not find a difference in the number of 
severe brain injuries between the experimental and the control 
groups neither in cUS nor in cerebral MRI. However, it must 
be kept in mind that the SafeBoosC II trial was not powered to 
look at the numbers of severe brain injuries between groups, 
as cUS and MRI were secondary and explorative outcomes, it 
could be speculated that the reduction of the cerebral burden 
of hypoxia was not of clinical relevance, but the burden was 
reduced by 58% in the experimental group (5). The cerebral 
oxygenation was only measured during the first 72 h of life, dur-
ing the period where most severe intracranial hemorrhages are 
known to occur (7). We did find more severe intracranial hem-
orrhages in the control group than in the experimental group, 
but the difference was insignificant. Measuring NIRS during 
the first 72 h of life in extremely preterm infants may poten-
tially reduce the number of severe brain injuries especially the 
early and intracranial hemorrhages, known to cause unfavor-
able neurodevelopmental outcomes, but the SafeBoosC II trial 
is not powered to make any final conclusions. Assessment of 
neurodevelopmental outcome at 2 y of age in this cohort is 
ongoing and will provide further information on the possible 
adverse effects of low cerebral oxygenation during the first 72 h 
of life in this population.
Feasibility of Neuroimaging in This Multicenter Trial
We showed that it is feasible though challenging to use central 
reading of cUS as an outcome measure in a randomized mul-
ticenter trial: most images could be centrally scored. Central 
reading of cUS in multicenter studies has previously proven 
possible (18). The percentage of uploaded cUS series decreased 
from day 7 onwards; at TEA, it was only 72%, and many infants 
were discharged or transferred to local hospitals at this age. As 
some lesions, such as cystic periventricular leukomalacia (19), 
cerebral atrophy (20), and posthemorrhagic ventricular dilata-
tion develop over time, it has been argued that it is necessary 
Figure 1. Flow chart from inclusion to term-equivalent age, number of 
uploaded serial cranial ultrasound scans in the two treatment groups.
Included in the SafeBoosC phase II feasibility trial
n = 166
Experimental group
n = 86
Control group
n = 80
Central overall scorea
n = 86
Death n = 2
cUS day 1
n = 74 (93%)
cUS day 4
n = 71 (91%)
cUS day 7
n = 73 (95%)
cUS day 14
n = 65 (95%)
cUS day 35
n = 67 (96%)
cUS TEA
n = 46 (66%)
cUS day 1
n = 71 (92%)
cUS day 4
n = 71 (96%)
cUS day 7
n = 65 (96%)
cUS day 14
n = 60 (92%)
cUS day 35
n = 52 (85%)
cUS TEA
n = 46 (79%)
cUS per protocol
n = 44 (55%)
a
 Reasons for no central overall cUS-score: too few uploaded images (n = 1), poor image quality (n = 3),
combination of both (n = 4) and death within few hours (n = 1)
Three infants without central cUS score died; experimental group (n = 2) control group (n = 1)
cUS as per protocol
n = 50 (65%)
Death n = 1
Death n = 3
Death n = 4
Death n = 3
Death n = 6
Death n = 4
Death n = 2
Death n = 4
Central overall scorea
n = 77
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to perform serial cUS until TEA in order to capture the full 
extent of brain injury (21). However, in one study, only 4% of 
the severe brain injuries was detected after day 35 (19). None 
of our infants scanned at TEA shifted category from no severe 
brain injury to severe brain injury, but we may potentially have 
missed some cases.
MRI at TEA was optional and performed in only 64% of the 
infants. This number was lower than we had expected, maybe 
because MRI at TEA was not standard clinical care of pre-
term infants in most participating centers, and an additional 
informed consent for MRI was required separately from the 
consent to the randomized intervention. This is a limitation of 
our study. The infants in the SafeBoosC II trial were followed 
closely by serial cUS, and it is possible that the parents felt they 
were already well informed about the extent of the brain injury 
and the risk of later adverse neurodevelopmental outcomes 
and therefore did not want to take part in an additional MRI 
scan where the infant might be sedated and admitted to the 
hospital for this purpose alone. In this study, two infants who 
had mild/moderate brain injury on early cUS because of IVH 
grade I-II findings were categorized as having severe injuries 
on MRI because of cerebellar hemorrhages that were not rec-
ognized on serial cUS. Therefore, MRI is important in addition 
to cUS (21). Furthermore, MRI at TEA is superior to cUS in 
predicting the risk of CP in preterm infants (10) and contrib-
utes with additional information to serial cUS when estimat-
ing risk of adverse neurodevelopmental outcome (18)—MRI at 
TEA therefore plays an important role in the risk stratification 
in these infants (11). In our study, the number of severe and 
mild/moderate brain injuries on MRI was similar in the con-
trol and the experimental groups.
In future, large multicenter randomized controlled trials 
studying neuroprotective interventions; only MRI-dedicated 
neuroimaging groups/centers might use MRI. The MRI pro-
tocol should be followed rigorously, in order to make sure that 
the timing, slice thickness, and quality are comparable for all 
infants. With high resolution MRI, mild injury might be easier 
to pick up and fewer patients are needed to prove differences 
in quantitative measures that are related to long-term outcome 
(22). It is essential to obtain knowledge on the possible effects 
(benefits or harms) of the neuroprotective interventions in the 
vulnerable and developing preterm brain. In this study, it was 
not possible to perform quantitative MRI analysis because of 
different scanner systems and image acquisitions.
Central vs. Local Readings cUS
The overall κ values for the local and the central readers were 
moderate to good for severe injuries and poor to moderate for 
mild/moderate injuries. These findings are consistent with pre-
viously published interobserver cUS studies (23–25).
Local readers have the advantage of real-time images, 
whereas the central readers have only selected still images 
for assessment. However, central readers are blinded to the 
treatment groups, which are important in randomized clini-
cal trials where blinding of the person performing the cUS is 
impossible, as in the SafeBoosC II trial. Central reading might 
be thus the preferred method of analyzing cUS images in ran-
domized multicenter studies (24) without blinded interven-
tion. The problems of poor image quality may be addressed by 
dedicated training in a future study.
Conclusions
The distribution of brain injury into no, mild/moderate, or 
severe injury did not differ among the groups neither for the 
overall cUS score nor for MRI. There was less severe brain 
injury in the experimental group as assessed by central reading 
of cerebral ultrasound, which is in line with the reduction of 
cerebral hypoxia in the experimental group of the SafeBoosC II 
trial, but MRI conducted at TEA in 64% of the infants did not 
support this finding. The problems in acquiring cUS and MRI 
data of good quality might be addressed by dedicated training. 
cUS as well as MRI images at TEA were often missing. Central, 
blinded readers of cUS achieved high interobserver agreement 
for severe brain injury. Large randomized clinical trials should 
be performed to evaluate the effect of the burden of cerebral 
hypoxia on brain injury in extremely preterm infants.
METHODS
Study Design and Population
One-hundred and sixty-six extremely preterm infants from eight 
European countries were included (1 June 2012 to 31 December 
2013) (5). The infants were randomized to either the experimental 
group or the control group. Infants in the experimental group were 
monitored with NIRS, and continuous cerebral tissue oxygenation 
levels were available for the clinician together with a dedicated treat-
ment guideline (4), listing possible interventions if the cerebral oxy-
genation level was out of range (55–85%). The infants in the control 
group were also monitored with cerebral NIRS, and the data were 
recorded but blinded to the clinicians. They were given standard care. 
In both groups, the cerebral NIRS monitoring was started within 3 h 
after birth and continued until 72 h of life (5).
The protocol of SafeBoosC II is published (3) and is available in 
full at www.safeboosc.eu. The study is registered at ClinicalTrial.gov, 
NCT01590316.
Cranial Ultrasound
On day 1 (any time during the first 24 h of life), 4 (±1), 7 (±1), 14 (±1), 
35 (±1), and at TEA (week 38 to 44) standardized cUS (six coronal 
and five sagittal images through the anterior fontanel and 1 through 
the mastoid window) was performed. The cUS was performed 
unblinded and according to local standard, either by the clinical staff 
or by a suitable qualified sonographer. Local unblinded investigators 
reported the cUS findings in an electronic record form. The images 
were anonymized and uploaded as DICOM files for central reading. 
The local scorings from the electronic record form were converted 
into predefined diagnoses (Table 4), which correlate to later develop-
mental outcomes (18,20,26,27).
Central reading was performed by two cUS readers (M.B. and 
C.H.) blinded to treatment group and medical history of the infants. 
Initial cUS images from two times 20 random infants were scored 
by the central readers to ensure common use of the scoring system. 
Then, the central readers scored all cUS series individually according 
to the predefined diagnoses (Table 4). Disagreements were resolved 
by consensus meetings. Each cUS was categorized on a three-level 
scale as no brain injury, mild/moderate brain injury, or severe brain 
injury (18,20,26,27). DICOM images were analyzed using the soft-
ware program OsiriX version 6.0. (Pixmeo, Geneva, Switzerland). 
Images uploaded in other formats were viewed in Preview.
The scores of all cUS images for each infant were combined into an 
overall cUS score reflecting the worst scan in any of the serial cUSs. 
In case of death, the overall cUS score would reflect the worst scan in 
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any of the cUSs performed before the time of death. Infants missing 
cUS examinations on more than two of the predefined time points 
were excluded from the analysis unless the brain injury was classified 
as severe in any of the existing images.
Magnetic Resonance Imaging
At TEA (corrected age 40–44 wk), the parents of the preterm infants 
were offered an MRI. The MRI procedure was performed according to 
local protocols; preferably on a 3T MRI system; if this was not avail-
able, images were acquired on a 1.5T system. T1- and T2-weighted 
images were used for brain injury scoring. The MRIs were anony-
mized and uploaded in DICOM format for central reading. A.M.P., 
C.H., M.F., and M.B. analyzed the MRIs blinded to treatment group, 
medical history of the infant, and cUS findings. MRIs were scored 
in consensus. The scoring was done according to a combination of 
previously published scoring systems (11,16,28). The scores were 
categorized into: normal brain (0–3 points), mild/moderate brain 
injury (4–11 points), and severe brain injury (12 points or more) as 
described by Kidokoro (16). All MRIs were evaluated in the software 
program OsiriX version 6.0.
Ethics
The SafeBoosC phase II feasibility multicenter trial was approved by 
each hospital’s local research ethics committee (Hopital Femme Mere 
Enfants, Lyon, France; Rigshospitalet, Copenhagen, Denmark; La 
Paz University Hospital, Madrid, Spain; Cork University Maternity 
Hospital, Cork, Ireland; Wilhelmina Children’s Hospital, Utrecht, The 
Netherlands; Medical University of Graz, Graz, Austria; Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; and 
Rosie Hospital, Cambridge University Hospitals, UK) and where 
required (Austria, Denmark, and France) by the competent authority 
responsible for medical devices. Parental written informed consent 
was mandatory before inclusion in the trial. Additional informed 
parental consent was obtained for MRI at TEA if MRI was not clini-
cally indicated or standard clinical care.
Statistics
Patient characteristics were summarized. The distribution of the brain 
injury severity on each day of the sequential cUS scans, the overall 
cUS score, and the MRI scores was tested between the groups by χ2 
test. The results were dichotomized into severe brain injury or no 
severe brain injury, and odds ratios were calculated. The percentage 
of the per-protocol images that were uploaded and scored was calcu-
lated for each day of the sequential cUS and for MRI. Kappa statistics 
was used to test the agreement between the two central readers and 
between the central and the local cUS readers. The statistics was per-
formed using the software RStudio Version 0.98.501 (Boston, MA) 
and IBM SPSS Statistics for Windows Version 20.0.0 (Armonk, NY).
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